VectorY and ShapeTX Partner to Advance AAV5-Based CNS Therapies
AMSTERDAM, BOSTON, and SEATTLE – Sept. 18, 2025 (cGxP.wire) – VectorY Therapeutics, a biotechnology company pioneering vectorized antibody therapies...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Bispecific Antibody cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech medtech innovation Monoclonal Antibody Neurodegenerative Disease Oncology oncology innovation Ophthalmology Orphan Drug orphan drug designation Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
AMSTERDAM, BOSTON, and SEATTLE – Sept. 18, 2025 (cGxP.wire) – VectorY Therapeutics, a biotechnology company pioneering vectorized antibody therapies...
OKLAHOMA CITY, Sept. 17, 2025 – Wheeler Bio, Inc., a U.S.-based contract development and manufacturing organization (CDMO), announced today...
HOUSTON, Sept. 16, 2025 – Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company specializing in regulatory T cell...
INDIANAPOLIS, Sept. 9, 2025, Eli Lilly and Company (NYSE: LLY) has launched a new global initiative, “Brain Health Matters,”...
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a late-clinical stage biotechnology company developing therapies for neurodegenerative diseases, has entered into a...
